AstraZeneca Sees Off Shareholder Revolt Over CEO’s Potential $25m Pay
Investors Upbeat Despite Vaccine Woes
Executive Summary
A few years ago Pascal Soriot claimed to be the sector’s worst paid CEO, but share price-linked bonuses have bumped up his remuneration, and shareholders have now approved a new plan.